Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry

Peer Review reports

Original Submission
11 Oct 2023	Submitted	Original manuscript
15 Oct 2023	Reviewed	Reviewer Report
3 Nov 2023	Reviewed	Reviewer Report
6 Nov 2023	Author responded	Author comments - David García-Azorín
8 Nov 2023	Author responded	Author comments - David García-Azorín
Resubmission - Version 2
6 Nov 2023	Submitted	Manuscript version 2
Publishing
9 Nov 2023	Editorially accepted
22 Nov 2023	Article published	10.1186/s10194-023-01690-2

Back to article page